AbbVie (NYSE: ABBV), announced today that Health Canada has approved SKYRIZI® (risankizumab) for the treatment of pediatric patients aged 6 to <18 years of age with moderate to severe plaque psoriasis ...

Tuesday that Health Canada has approved SKYRIZI (risankizumab) to treat children with moderate to severe plaque psoriasis. The treatment will be gi ...

There’s an interesting relationship between psoriasis and exercise: While the condition can make playing sports and working ...

Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...

New Delhi: Psoriasis is often mistaken for a skin condition characterised by red, scaly patches, but its impact extends far ...

At Fall Clinical 2026, Joel Gelfand, MD, MSCE, reviewed GLP-1 candidacy, weight conversations, and an upcoming monotherapy ...

Everyday Health shares their favorite psoriasis organizations to help you educate yourself, spread awareness, and connect ...

Psoriasis can follow you into the bedroom, turning what should be an enjoyable moment into a worry about what someone might ...

A Japanese case report of co-localized psoriasis and vitiligo reveals that IL-23 blockade cleared psoriasis but not vitiligo, ...

Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...

Research on psoriasis touches every aspect of the disease, including the role of nutrition, weight loss, the body’s microbiome, and treatments. While some researchers focus their attention on coming ...

I’ve had psoriasis since I was 5 years old. It started as a little patch on my left ankle—I remember thinking, What’s this ...